Participants recruited that pass the inclusion and exclusion criteria

Malaria

Falciparum Malaria

Vivax Malaria

Three days according to body weight (Days 0, 1 and 2). Correct drug dosage will be determined using the dosing chart (in accordance with national treatment guidelines).

Arthemeter-lumefantrine

Chloroquine according to body weight as a total dose of 25mg base/kg over 3 days (10 mg base/kg on Day 0; 10 mg base/kg on Day 1 and 5 mg base/kg on Day 2). Primaquine will be withheld for 28 days. It will be given after Day 28 follow-up, at 0.25 mg base/kg per day for 14 days.

Chloroquine

TES Artemether-lumefantrine for Pf and Chloroquine (CQ) for Pv

Efficacy and Safety of Artemether-lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria and Chloroquine for the Treatment of Plasmodium Vivax in the Philippines

Development of danger signs or severe malaria on day 1, day 2 or day 3 in the presence of parasitaemia; Parasitaemia on day 2 higher than day 0 count irrespective of axillary temperature; Parasitaemia on day 3 with axillary temperature ≥37.5 degree celsius; Parasitaemia on day 3 ≥25% of count on day 0.

Development of danger signs or severe malaria on any day from day 4 to day 28 in the presence of parasitaemia, without previously meeting any of the criteria of Early Treatment Failure; Presence of parasitaemia and axillary temperature ≥37.5 degree celsius (or history of fever in low/moderate transmission areas) on any day from day 4 to day 28, without previously meeting any of the criteria of Early Treatment Failure.

Absence of parasitaemia on day 28 irrespective of axillary temperature without previously meeting any of the criteria of Early Treatment Failure or Late Clinical Failure or Late Parasitological Failure.

Fe Esperanza J. Espino, MD, PhD

Principal Investigator, Head of Parasitology Department

Research Institute for Tropical Medicine, Philippines

World Health Organization

6 volunteers to be challenged with the infected with +/-3 mosquito bites from batch 413ABM

6 volunteers to be challenged with the infected with +/-3 mosquito bites from batch 414WRR

6 volunteers to be challenged with the infected with +/-3 mosquito bites from batch 418JAL

6 volunteers to be challenged with the infected with +/-3 mosquito bites from batch 413ABM
413ABM: +/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 413ABM

Group 1

6 volunteers to be challenged with the infected with +/-3 mosquito bites from batch 414WRR
414WRR: +/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 414WRR

Group 2

6 volunteers to be challenged with the infected with +/-3 mosquito bites from batch 418JAL
418JAL: +/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 418JAL

Group 3

Total

Sex: Female, Male

Region of Enrollment

Thick blood smear was performed to patients daily on days 7 to 23, and every other day until day 29. Any prove of P. vivax infection was considered positive and confirmed later by real time polymerase chain reaction (rPCR).

Infection for P. Vivax

Overall Study

Sócrates Herrera MD, principal investigator

MALARIA

FEVER

Sweating Fever

Chills

ANEMIA

+/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 413ABM

413ABM

+/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 414WRR

414WRR

+/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 418JAL

parasitemia/отёк

TES Artemether-lumefantrine for Pf and Chloroquine (CQ) for Pv

Evaluation of Reproducibility of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers

Самая полная база данных о лекарственных травах, подтвержденная наукой